Net profit of Jagsonpal Pharmaceuticals declined 65.77% to Rs 10.95 crore in the quarter ended December 2025 as against Rs 31.99 crore during the previous quarter ended December 2024. Sales declined 1.46% to Rs 72.95 crore in the quarter ended December 2025 as against Rs 74.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales72.9574.03 -1 OPM %22.3021.38 - PBDT18.9917.90 6 PBT16.6015.49 7 NP10.9531.99 -66 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals has allotted 56,571 equity shares under ESOP on 18 November 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,34,49,398 (constituting of 6,67,24,699 equity shares of Rs. 2/- each) to Rs. 13,35,62,540 (constituting of 6,67,81,270 equity shares of Rs. 2/- each).Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals rose 9.69% to Rs 12.57 crore in the quarter ended September 2025 as against Rs 11.46 crore during the previous quarter ended September 2024. Sales declined 0.29% to Rs 74.47 crore in the quarter ended September 2025 as against Rs 74.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales74.4774.69 0 OPM %22.0821.81 - PBDT19.2017.71 8 PBT16.8115.37 9 NP12.5711.46 10 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live News